Barclays maintains Ascendis Pharma at Overweight, raises price target to $341 from $329

Barclays reiterated its Overweight rating on Ascendis Pharma and increased its price target to $341 from $329, suggesting a 23.8% upside from the Nov 13 close. Recent analyst price targets for the company range from $290 to $356.

Original reporting
Published Nov 16, 2026, 3:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Ascendis Pharma at Overweight, raises price target to $341 from $329 — source image
Decision brief

The 30-second read

$ASNDBullishMed
01

Why it matters

The upgrade signals confidence in the company's pipeline and may attract new capital.

02

Market read

Analyst price target changes can move small-cap biotech stocks; traders may consider adjusting positions.

03

What to watch

Potential regulatory or trial setbacks not reflected in the target.

Relevance 7/10Novelty 7/10Timing: today

Background

Barclays maintains an Overweight rating on Ascendis Pharma, adjusting its price target upward.

Company-level read

Ticker impact

$ASNDBullishHigh confidence
Context

Barclays raised Ascendis Pharma's price target to $341 from $329, indicating a bullish outlook.

Expected impact

upward pressure as investors price in the higher target

Evidence & confidence

The new target implies a 23.8% upside from the recent close, likely prompting buying interest.

Market effects

Positive signal for the biotech sector may lift peers.

Limited to US biotech investors.

Minor, confined to niche biotech investors.

Counterpoint

Target raise may be premature if upcoming trial data disappoints.

Key entities

  • Barclays

    Investment bank providing the rating and price target.

  • Ascendis Pharma

    Biotech firm whose stock is being re-evaluated.

Related articles

$ASNDMed

TD Cowen raises Ascendis Pharma stock price target on revenue beat

TD Cowen raised its price target for Ascendis Pharma (ASND) to $352, citing strong Q3 revenue beats across its products. Revenue grew 86% YoY with a 92% gross margin. The company reaffirmed long-term revenue targets of €5B by 2030 and €10B by 2035. ASND stock trades near its 52-week high at $266.31. Other analysts also raised targets and maintained positive ratings.

$ASNDMedAI 8/10

Ascendis Pharma AS (ASND) Q3 2026 Earnings Call Highlights: Revenue Surges 89% as YORVIPATH

Ascendis Pharma AS reported Q3 2026 revenue up 89%, driven by YORVIPATH. CEO Jan Mikkelsen discussed new therapeutic areas, ex-US growth, and YUVIWEL's potential. The company expects steady US uptake and EUR5B 2030 sales. CFO Scott Smith noted EUR330M spent on share buybacks, with EUR600M operating cash flow guided for 2026. Margins improved to mid-40s, with no major commercial infrastructure changes expected.

$ASNDHighAI 8/10

Ascendis Pharma earnings analysis: questions answered and next catalysts

Ascendis Pharma (ASND) reported Q3 2026 earnings, beating revenue and EPS estimates. Shares rose 2.93% to $266.88. Key drugs showed strong demand, and the company increased its cash flow outlook. Management addressed growth, funding, and competition. Next catalysts include regulatory decisions, clinical trials, and market expansion. Analysts debate valuation and future growth prospects.

$ASNDHighAI 8/10

Ascendis (ASND) Q3 2026 Earnings Call Transcript

Ascendis (ASND) reported Q3 2026 product revenue of €366 million, up 89% YoY. Key drivers: growth in existing products (Yorvipath, Yuvivel, Skytrofa), indication expansions, and new products. Yorvipath revenue was €291 million, up 103% YoY. Yuvivel and Skytrofa also showed strong demand. The company aims for €5 billion in annual revenue by 2030.

HighAI 8/10

Why is Ascendis Pharma stock climbing today?

Ascendis Pharma's stock rose 0.5% in pre-market trading after its Q3 2026 earnings beat estimates, with adjusted EPS of €1.08 vs. €0.80 and revenue of €369.7M vs. €363.0M. YORVIPATH sales grew 103% YoY to €291M. The company also repurchased 2M shares for $459M and received positive EU regulatory opinions for TransCon CNP.